KR20240004837A - 항-5t4 항체 및 이의 용도 - Google Patents

항-5t4 항체 및 이의 용도 Download PDF

Info

Publication number
KR20240004837A
KR20240004837A KR1020237041483A KR20237041483A KR20240004837A KR 20240004837 A KR20240004837 A KR 20240004837A KR 1020237041483 A KR1020237041483 A KR 1020237041483A KR 20237041483 A KR20237041483 A KR 20237041483A KR 20240004837 A KR20240004837 A KR 20240004837A
Authority
KR
South Korea
Prior art keywords
seq
nos
ser
thr
gly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237041483A
Other languages
English (en)
Korean (ko)
Inventor
오렌 보긴
리앗 다싸
Original Assignee
임뮤노라이즌 엘티디.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 임뮤노라이즌 엘티디. filed Critical 임뮤노라이즌 엘티디.
Publication of KR20240004837A publication Critical patent/KR20240004837A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020237041483A 2021-05-04 2022-05-02 항-5t4 항체 및 이의 용도 Pending KR20240004837A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163183636P 2021-05-04 2021-05-04
US63/183,636 2021-05-04
PCT/IL2022/050451 WO2022234570A1 (en) 2021-05-04 2022-05-02 Anti-5t4 antibodies and uses thereof

Publications (1)

Publication Number Publication Date
KR20240004837A true KR20240004837A (ko) 2024-01-11

Family

ID=83932628

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237041483A Pending KR20240004837A (ko) 2021-05-04 2022-05-02 항-5t4 항체 및 이의 용도

Country Status (11)

Country Link
US (1) US20240228658A1 (https=)
EP (1) EP4334362A4 (https=)
JP (1) JP2024517760A (https=)
KR (1) KR20240004837A (https=)
CN (1) CN117279951A (https=)
AU (1) AU2022270453A1 (https=)
BR (1) BR112023023086A2 (https=)
CA (1) CA3217716A1 (https=)
IL (1) IL308203A (https=)
MX (1) MX2023013018A (https=)
WO (1) WO2022234570A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024183811A1 (en) * 2023-03-08 2024-09-12 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Anti-5t4 antibodies and uses thereof
CN121002067A (zh) * 2023-04-03 2025-11-21 非同（成都）生物科技有限公司 抗5t4抗体及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012009709A1 (en) * 2010-07-16 2012-01-19 Sudhir Paul Hiv cd4 binding site based covalent immunogen compositions
WO2015051159A1 (en) * 2013-10-02 2015-04-09 The Rockefeller University Amyloid protofibril antibodies and methods of use thereof
MX384198B (es) * 2014-12-19 2025-03-14 Chiome Bioscience Inc Proteina de fusion que comprende tres dominios de union a 5t4 y cd3.
SG11202008399QA (en) * 2018-03-12 2020-09-29 Genmab As Antibodies
CN116096754A (zh) * 2020-05-04 2023-05-09 免疫里森公司 前体三特异性抗体构建体及其使用方法

Also Published As

Publication number Publication date
US20240228658A1 (en) 2024-07-11
WO2022234570A1 (en) 2022-11-10
AU2022270453A1 (en) 2023-12-21
BR112023023086A2 (pt) 2024-01-30
EP4334362A4 (en) 2025-04-16
CA3217716A1 (en) 2022-11-10
MX2023013018A (es) 2024-01-18
EP4334362A1 (en) 2024-03-13
CN117279951A (zh) 2023-12-22
IL308203A (en) 2024-01-01
JP2024517760A (ja) 2024-04-23

Similar Documents

Publication Publication Date Title
CN105968206B (zh) 抗erbb3抗体
CN111867630A (zh) 靶向cldn18.2的抗体、双特异性抗体、adc和car及其应用
WO2023208203A1 (en) Anti-ccr8 antibodies and uses thereof
JP2019518459A (ja) Ｌａｇ−３抗体、その抗原結合フラグメント、およびそれらの医薬的用途
WO2022042719A1 (zh) 抗vegf-抗pd-l1双特异性抗体、其药物组合物及用途
EP4292611A1 (en) Anti-cd112r antibody and use thereof
KR20220042258A (ko) 항 tigit 항체 및 그의 응용
KR20230154020A (ko) 클라우딘-6에 대한 항체 및 이의 용도
CN114641502A (zh) 一种新的抗tigit抗体
TW202337908A (zh) 抗b7-h7抗體或其抗原結合片段及製備方法與應用
WO2022222992A1 (en) Antibodies binding trop2 and uses thereof
WO2023109888A1 (zh) 抗ang2-vegf双特异性抗体及其用途
IL322846A (en) Antibodies, antigen-binding fragments and methods of use
KR20240004837A (ko) 항-5t4 항체 및 이의 용도
EP4349867A1 (en) Specific binding protein targeting pd-l1 and cd73
EP4428154A1 (en) Anti-cldn18.2 antibody and use thereof
CN114276451B (zh) 靶向CD3e/g的抗体或其抗原结合片段、其制备和应用
CN117396220A (zh) 抗nkg2d抗体及其用途
EA053012B1 (ru) Антитела к 5t4 и варианты их применения
WO2024032761A1 (en) Ligand-cytotoxicity drug conjugates and pharmaceutical uses thereof
US20240301062A1 (en) Anti-cd3 multispecific antibodies and methods of use
WO2012057765A1 (en) Recombinant anti-cd19 monoclonal antibodies
WO2025146128A1 (zh) 抗liv-1的抗体及其用途
WO2024184811A1 (en) Anti-cd3 multispecific antibodies and methods of use
HK40119169A (zh) 配体-细胞毒性药物偶联物及其药物用途

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20231130

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20250319

Comment text: Request for Examination of Application